Drugs / KX2-361
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02326441 | Dec 2014 → Jul 2017 | cancer | Athenex, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KX2-361 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02326441 ↗ |
| Known as | KX-02 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297299 ↗ |
| Modality | Small molecule | — CHEMBL4297299 ↗ |